DALLAS, April 18, 2005 (PRIMEZONE) -- John Pentony, Publisher of TalkingStocks.com, announced today the web site has posted a new interview with Paul Desjourdy, President of Symbollon Pharmaceuticals, Inc. (OTCBB:SYMBA), discussing the recently announced funding for phase III trials on IoGen. Mr. Desjourdy discusses the potential market for IoGen and the agreement with Bioaccelerate Holdings, Inc. to fund the Phase III development of IoGen.
To listen to the TalkingStocks interview with Paul Desjourdy of Symbollon Pharmaceuticals, please visit:
http://talkingstocks.com/interviews/SYMBA_041805.php
About IoGen
IoGen is an oral dosage form of Symbollon's technology, which generates molecular iodine in situ in the stomach of the patient. IoGen is entering Phase III clinical trials for the treatment of moderate to severe cyclic breast pain and tenderness (mastalgia) associated with fibrocystic breast disease (FBD). FBD is a benign breast condition characterized by lumpiness, breast pain and tenderness. FBD affects approximately 30 to 50% of the women of childbearing age, which represents about 20 to 33 million women in the United States. It has been estimated that moderate to severe mastalgia occurs in approximately 11 to 20% of the women of childbearing age, or about 7 to 13 million women in the United States.
Besides causing pain and discomfort, this condition can mimic the appearance of breast cancer on mammograms, leading to false positives. In addition, fibrocystic changes can also hide true cancers, and women with fibrocystic breast disease may also have a greater tendency toward breast cancer.
The cause of cyclic breast pain is unclear, though higher than normal levels of the hormone levels may be involved. Conventional treatment for cyclic mastalgia involves anti-inflammatory medications and, sometimes, hormonal treatments.
About Symbollon
Symbollon Pharmaceuticals, Inc. (OTCBB:SYMBA) is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its molecular iodine technology. Symbollon already has completed Phase I and II clinical trials evaluating IoGen as a potential treatment for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD). FBD is a condition that affects approximately 20 to 33 million women in the U.S., and there are approximately 7 to 13 million women suffering from clinical cyclic mastalgia. The Company believes IoGen also may be useful in treating and/or preventing endometriosis, ovarian cysts, and premenopausal breast cancer. For more information about Symbollon, visit the company's website at http://www.symbollon.com/.
About StockGuru.com and TalkingStocks.com
StockGuru.com and TalkingStocks.com are two of the leading destinations on the Internet for information on small and micro cap companies. Companies interested in our services may contact our Publisher, John Pentony, to discuss featuring a company on our web sites. To contact our Publisher, either telephone: (972) 731-8621 or email publisher@stockguru.com.
Symbollon Safe Harbor Statement
This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) future clinical trial results will support the use of IoGen for the treatment of fibrocystic breast disease, (ii) the clinical data acquired from Mimetix Inc. will be acceptable exposure data for IoGen, (iii) Symbollon will be able to obtain the resources necessary to complete the Phase III trials for IoGen and the other clinical development activities related to IoGen and to continue its operations, (iv) IoGen will successfully complete the regulatory approval process, (v) competitive products will receive regulatory approval, (vi) the Company's ability to enter into new arrangements (including with respect to IoGen) with corporate partners and (vii) such other factors as may be disclosed from time- to-time in the Company's reports as filed with the Securities and Exchange Commission. Given these uncertainties, current or prospective investors are cautioned not to place undue reliance on any such forward-looking statements.
Disclosure: Pentony Enterprises LLC and TalkingStocks.com LLC have been compensated $22,000 by the company for profile coverage. Neither TalkingStocks.com, LLC, nor Pentony Enterprises, LLC, are registered investment advisers or broker/dealers. TalkingStocks.com, LLC and Pentony Enterprises, LLC makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.